Identification of tryptophan metabolism- and immune-related genes signature and prediction of immune infiltration landscape in bladder urothelial carcinoma.
Bladder urothelial carcinoma
biomarkers
immune
prognosis
tryptophan metabolism
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
08
2023
accepted:
12
10
2023
medline:
14
11
2023
pubmed:
13
11
2023
entrez:
13
11
2023
Statut:
epublish
Résumé
Tryptophan metabolism is indirectly involved in immune tolerance and promotes response to anticancer drugs. However, the mechanisms underlying tryptophan metabolism and immune landscape in bladder urothelial carcinoma (BLCA) are not fully understood. A BLCA dataset containing 406 tumor samples with clinical survival information and 19 normal samples were obtained from the Cancer Genome Atlas database. The validation set, GSE32894, contained 223 BLCA tumor samples with survival information, and the single-cell dataset, GSE135337, included seven BLCA tumor samples; both were obtained from the gene expression omnibus database. Univariate and multivariate Cox regression analyses were conducted to evaluate clinical parameters and risk scores. Immune infiltration and checkpoint analyses were performed to explore the immune landscape of BLCA. Single-cell analysis was conducted to further identify the roles of model genes in BLCA. Finally, NAMPT expression in BLCA and adjacent tissues was detected using RT-qPCR, CCK-8 and Transwell assays were conducted to determine the role of NAMPT in BLCA cells. Six crossover genes (TDO2, ACAT1, IDO1, KMO, KYNU, and NAMPT) were identified by overlap analysis of tryptophan metabolism-related genes, immune-related genes, and differentially expressed genes (DEGs). Three biomarkers, NAMPT, IDO1, and ACAT1, were identified using Cox regression analysis. Accordingly, a tryptophan metabolism- and immune-related gene risk model was constructed, and the patients were divided into high- and low-risk groups. There were significant differences in the clinical parameters, prognosis, immune infiltration, and immunotherapy response between the risk groups. RT-qPCR revealed that NAMPT was upregulated in BLCA samples. Knocking down NAMPT significantly inhibited BLCA cell proliferation, migration, and invasion. In our study, we constructed a tryptophan metabolism- and immune-related gene risk model based on three biomarkers, namely NAMPT, IDO1, and ACAT1, that were significantly associated with the progression and immune landscape of BLCA. The risk model could effectively predict patient prognosis and immunotherapy response and can guide individualized immunotherapy.
Identifiants
pubmed: 37954600
doi: 10.3389/fimmu.2023.1283792
pmc: PMC10637370
doi:
Substances chimiques
Tryptophan
8DUH1N11BX
Tryptophan Oxygenase
EC 1.13.11.11
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1283792Informations de copyright
Copyright © 2023 Zhou, Qin, Zhang, Zhao and Xue.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor WC declared a shared parent affiliation with the authors at the time of review.
Références
Cell Host Microbe. 2018 Jun 13;23(6):716-724
pubmed: 29902437
Innovation (Camb). 2021 Jul 01;2(3):100141
pubmed: 34557778
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Immunity. 2005 May;22(5):633-42
pubmed: 15894280
Ann Thorac Surg. 2001 Sep;72(3):859-66
pubmed: 11565671
Oncogene. 2020 Mar;39(11):2437-2449
pubmed: 31974474
Cancer Treat Rev. 2023 Apr;115:102530
pubmed: 36898352
Transl Res. 2016 Jan;167(1):67-79
pubmed: 26297050
Mol Cell. 2021 Jun 3;81(11):2290-2302.e7
pubmed: 33831358
Front Immunol. 2014 Jul 14;5:327
pubmed: 25071785
Nat Rev Cancer. 2021 Feb;21(2):104-121
pubmed: 33268841
Nat Rev Drug Discov. 2019 May;18(5):379-401
pubmed: 30760888
Int J Cancer. 2021 Dec 15;149(12):2099-2115
pubmed: 34480339
BJU Int. 2021 Apr;127(4):445-453
pubmed: 32794357
Mol Cancer. 2021 Feb 5;20(1):28
pubmed: 33546704
Theranostics. 2022 Aug 29;12(14):6291-6307
pubmed: 36168624
Trends Immunol. 2016 Mar;37(3):193-207
pubmed: 26839260
Nat Rev Clin Oncol. 2020 Dec;17(12):725-741
pubmed: 32760014
Rheumatology (Oxford). 2002 May;41(5):572-81
pubmed: 12011383
Genome Med. 2020 May 27;12(1):47
pubmed: 32460812
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
Cancer Immunol Res. 2021 Sep;9(9):1008-1023
pubmed: 34285037
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
Cancer Res. 2020 Feb 15;80(4):890-900
pubmed: 31857293
J Oncol. 2022 Sep 12;2022:7679652
pubmed: 36131793
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Eur Urol. 2022 Jan;81(1):95-103
pubmed: 34742583
Immunity. 2022 Feb 8;55(2):324-340.e8
pubmed: 35139353
Nat Rev Endocrinol. 2015 Sep;11(9):535-46
pubmed: 26215259
Front Immunol. 2014 Apr 23;5:185
pubmed: 24795727
CA Cancer J Clin. 2020 Sep;70(5):404-423
pubmed: 32767764
Semin Cancer Biol. 2018 Oct;52(Pt 1):17-25
pubmed: 28870843
CPT Pharmacometrics Syst Pharmacol. 2013 Oct 16;2:e79
pubmed: 24132163
FEBS J. 2023 Jan;290(1):7-27
pubmed: 34687129
Proc Natl Acad Sci U S A. 2022 Dec 27;119(52):e2203894119
pubmed: 36534812
Cancer Res. 2018 May 1;78(9):2233-2247
pubmed: 29440146
Cancer Discov. 2021 May;11(5):1067-1081
pubmed: 33504580
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Annu Rev Pathol. 2021 Jan 24;16:223-249
pubmed: 33197221
Science. 2017 Jul 28;357(6349):
pubmed: 28751584
Signal Transduct Target Ther. 2021 Jan 1;6(1):2
pubmed: 33384409
Curr Opin Immunol. 2021 Jun;70:7-14
pubmed: 33418116